II. Indications
- Second-Line DMARD in Rheumatoid Arthritis- Especially Antinuclear Antibody positive
- May be used in triple combination with Methotrexate and Sulfasalazine- Indicated in moderate to severe disease refractory to single conventional synthetic DMARD
 
 
- Systemic Lupus Erythematosus
- 
                          Malaria Prophylaxis and treatment- Regions without Chloroquine resistance, non-severe infections
 
- Rheumatologic off-label uses
- Infectious off-label uses
- NOT indicated in COVID-19 outside of Clinical Trials- Initial studies as of May 2020 suggest no benefit and adverse effect risk (including QTc Prolongation)
 
III. Contraindications
- 
                          G6PD Deficiency
                          - Risk of Hemolytic Anemia
 
IV. Mechanism
- Antimalarial agent used in rheumatic disease
- Modified Chloroquine to reduce Retinopathy risk
- Blocks Sodium and Potassium channels
V. Dosing: Rheumatologic Disorders
- Varies significantly based on use- Lower doses are used in infectious disease
 
- Dosing: Adults- Initial: 400 to 600 mg (may consider starting at 200 mg) orally twice daily
- Maximum: 600 mg/day
- Expect symptom improvement by 2 to 4 months (discontinue if no effect by 6 months)
- Taper after 1-2 years when stable to 200 mg orally daily
 
VI. Dosing: Malaria
- 
                          Malaria Prophylaxis
                          - Start 1-2 weeks before travel and continue for 4 weeks after leaving Malaria endemic region
- Adult: 400 mg salt (310 mg base) orally once weekly
- Child: 6.5 mg/kg salt (5 mg/kg base up to adult dose) orally once weekly
 
- 
                          Malaria Treatment- Adult: 800 mg salt (620 mg base) to start, then 400 mg salt (310 mg base) at 6, 24 and 48 hours after initial dose
- Child: 12.9 mg/kg salt (10 mg/kg base) to start, then 6.5 mg/kg salt (5 mg/kg mg base) at 6, 24 and 48 hours after initial dose
 
VII. Precautions
- One tablet may be lethal in children (lethal dose 30 mg/kg)
- Considered safe in pregnancy (all trimesters), despite initially labeled category D
VIII. Adverse Effects
- Eye-related Adverse Effects- Epithelial Keratopathy and other Corneal disorders
- Retinopathy- Uncommon to Rare (contrast with Chloroquine)
 
 
- Neurologic adverse effects- Early toxicity (subsides within 2 weeks)
- Late toxicity requires medication discontinuation- Tinnitus
- Decreased Hearing acuity
 
- Very rare toxicity- Myopathy or muscular weakness
 
- Other adverse effects- Confusion or Delirium
- Extrapyramidal Side Effects
- Hallucinations
- Seizures
 
 
- Gastrointestinal adverse effects
- Endocrine Adverse Effects
- Hematologic Adverse Effects
- 
                          Electrolyte adverse effects- Hypokalemia (in toxicity)
 
- Cardiovascular adverse effects- Palpitations
- Hypotension (in toxicity)
- Premature Atrial Contractions
- Cardiomyopathy
- QRS Widening (in toxicity)
- QTc Prolongation (with risk of Ventricular Tachycardia or Drug-Induced Torsades de Pointes)- Increased risk when combined with other agents causing QTc Prolongation (e.g. Azithromycin)
 
 
IX. Pharmacokinetics
- Onset: 2-4 hours after oral dose
- Half-Life: 20 to 40 days
- Lethal dose in young children as low as 750 mg
X. Efficacy: Rheumatoid Arthritis
- Response in 70-80% of cases
- Response occurs in 3-6 months
- Highest efficacy when used early in disease process
XI. Safety
- Considered safe in Lactation
- In pregnany, use if benefit outweighs risk
- Monitoring- Routine Eye Exam every 6-12 months (including a baseline exam)
- Complete Blood Count (CBC) periodically
 
XII. Management: Hydroxychloroquine Overdose or Toxicity
- See ABC Management
- Activated Charcoal if <1 hour from ingestion and patient maintaining own airway
- Ventricular Arrhythmia- Cardioversion
- Lidocaine
 
- 
                          Wide QRS
                          - Bicarbonate (caution if Hypokalemia)
 
- 
                          Hypokalemia
                          - Potassium Replacement (caution)
 
- Seizures
- Hypotension
- Other measures- ECMO (refractory cardiovascular failure)
 
XIII. Resources
- Hydroxychloroquine Tablet (DailyMed)
XIV. References
- (2020) LexiComp, Hydroxychloroquine, accessed 5/6/2020
- Tomaszekski (2020) Crit Dec Emerg Med 14(4):32
- Matteson (2000) Mayo Clin Proc 75:669-74 [PubMed]
- Pincus (1999) Clin Rheumatol 17(6 Suppl 18):S2-S124 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| hydroxychloroquine (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| HYDROXYCHLOROQUINE 100 MG TAB | Generic | $0.18 each | 
| HYDROXYCHLOROQUINE 200 MG TAB | Generic | $0.21 each | 
